Targovax to Present at NeoAg Summit 2018

OSLO, Nov. 16, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that CMO Magnus Jäderberg will present at the NeoAg Summit 2018 (formerly Neoantigen Summit) in Boston

Advertisement

NeoAg Summit 2018Date: 16 November 2018 Presenter: Dr. Magnus Jäderberg, CMOPresentation time: 11:00 ETVenue: Hyatt Regency Cambridge, Boston.

Advertisement

Title: TG01, a neo-antigen specific vaccine targeting RAS mutations in solid tumours

Presentation slides will be available on www.targovax.com/Investors.

For further information, please contact:Renate Birkeli, Investor RelationsPhone: +47-922-61-624Email: [email protected] Media and IR enquires:Andreas Tinglum - Corporate Communications (Norway)Phone: +47-9300-1773Email: [email protected] Simon Conway/Stephanie Cuthbert - FTI Consulting (International)Phone: +44-20-3727-1000Email: [email protected]

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/targovax/r/targovax-to-present-at-neoag-summit-2018,c2673975

 

 

View original content:http://www.prnewswire.com/news-releases/targovax-to-present-at-neoag-summit-2018-300751943.html

SOURCE Targovax